Home>Topics>Stocks>ViroPharma

ViroPharma VPHM

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Shire PLC

      Stock Reports

      Tue, 22 Jul 2014

      However, we have a positive view on the ViroPharma acquisition, which capitalizes on Shire ..... Shire completed the acquisition of ViroPharma in early 2014. Sales of Shire's leading ..... We think that Cinryze (from the ViroPharma acquisition) is likely to reach $700

    2. As Expected, AbbVie and Shire Agree on Takeover Terms; Deal Expected to Close in 4Q

      Commentary

      Fri, 18 Jul 2014

      billion from strong sales of Vyvance (up 20%) and other products and the inclusion of Cinryze sales from the acquisition of Viropharma . The strong top-line growth, coupled with an improving operating margin, resulted in adjusted non-GAAP EPS growth of

    3. Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment

      Headlines

      Tue, 8 Jul 2014

      By Scott Matusow : Written by Scott Matusow and Kyle Dennis Last year, Halozyme ( HALO ) was one of the high flying biotech stocks, increasing in value four-fold. Much of the big run occurred when we wrote that a company director bought 50,000 shares in the high $6 range. This same director bought

    4. Shire's Strong First Quarter Benefited From ViroPharma and Underlying ADHD Demand

      Commentary

      Thu, 1 May 2014

      cutting success, and the close of the ViroPharma acquisition. Management also lowered ..... million in two months since the ViroPharma acquisition), and Lialda (up $28 million or 28%). Excluding ViroPharma , sales were up 11%. Firazyr sales

    5. Shire's 2013 In Line; Raising Our Fair Value on Higher ViroPharma Profit, Lower Cost of Capital

      Commentary

      Fri, 14 Feb 2014

      earlier-than-expected close to the ViroPharma acquisition. We continue to have a positive take on the ViroPharma acquisition, which strengthens the ..... incorporating more accretion from the ViroPharma acquisition into our 2014 forecast

    6. New Morningstar Analyst Report for ViroPharma , Inc.

      Stock Reports

      Mon, 11 Nov 2013

      in midstage testing, the future of ViroPharma 's lead pipeline candidate maribavir ..... the drug failed in a Phase III trial. ViroPharma has finally secured FDA approval for ..... which should help reaccelerate growth. ViroPharma boasts the only FDA-approved product

    7. Shire's ViroPharma Acquisition Has Clear Synergies with Rare Disease Business

      Commentary

      Mon, 11 Nov 2013

      Shire has announced plans to acquire ViroPharma for $50 per share, or $4.2 billion ..... which amounts to a 64% premium to ViroPharma 's share price in September (prior ..... 25 per share fair value estimate for ViroPharma . However, after including $150 million

    8. Post-Vancocin, ViroPharma Remains Overvalued Due to Uncertainty Surrounding Pipeline Potential

      Commentary

      Thu, 1 Aug 2013

      ViroPharma 's second-quarter results continued to reflect the firm's ongoing transformation ..... with strong Cinryze sales growth offsetting Vancocin’s decline. ViroPharma maintained its full-year guidance, which is in line with our expectations

    9. ViroPharma Focuses on Pipeline as Earnings Slide in 1Q

      Commentary

      Wed, 1 May 2013

      ViroPharma 's VPHM first-quarter results continued to reflect the firm's ongoing transformation ..... highly profitable antibiotic company into a rare-disease operation. ViroPharma lowered its full-year product sales guidance because of the steep

    10. Generic Competition for Vancocin Causes ViroPharma's Earnings to Hit Trough in 2012

      Commentary

      Wed, 27 Feb 2013

      During the fourth quarter, ViroPharma VPHM reported product sales that slightly ..... competition for Vancocin, and ViroPharma 's former breadwinning antibiotic ..... valuation remains heavily tied to ViroPharma 's ability to extend Cinryze

    « Prev12345Next »
    Content Partners